Yeji

$OMER

OMEROS CORP

Runway:28 mo
NasdaqMarket cap: —CIK 0001285819

Upcoming catalysts

2 surfaced
NDA/BLA filedDate TBD
$OMEROMEROS CORP
narsoplimab · hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)
“in March 2025, the Company resubmitted to U.S. Food and Drug Administration ("FDA") the biologics license application ("BLA") seeking regulatory approval for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy ("TA-TMA"). The resubmission was accepted for review by FDA as a class 2 resubmission”
NDA/BLA filedDate TBD
$OMEROMEROS CORP
narsoplimab · hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)
“the U.S. Food and Drug Administration accepted for review the resubmission of the Biologics License Application for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy”

Drug pipeline

yartemlea
narsoplimab
hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)
OMS201
Urinary Calculi
Biological: narsoplimab
Thrombotic Microangiopathies
OMS906
Paroxysmal Nocturnal Hemoglobinuria
OMS643762
Huntington's Disease
OMS103HP-S
Meniscal Tear
OMS721
Thrombotic Microangiopathies
OMS103HP
Knee Injuries
Part 1 OMS302
Intraocular Lens Replacement
OMS302
Intraocular Lens Replacement
OMS302 Solution
Cataract
OMS906 study drug
Paroxysmal Nocturnal Hemoglobinuria
OMS721 (narsoplimab)
Thrombotic Microangiopathies

Recent & active trials

NCTDrugPhaseStatusPrimary completion
NCT06298955OMS906 study drugPhase 2Recruiting2026-12-01
NCT06209736OMS906 study drugPhase 2Recruiting2026-01-01
NCT05855083Biological: narsoplimabPhase 2Recruiting2025-12-01
NCT05889299OMS906Phase 1Completed2025-11-03
NCT05972967OMS906Phase 2Completed2024-10-10
NCT03608033OMS721 (narsoplimab)Phase 3Terminated2024-01-12
NCT03205995OMS721 (narsoplimab)Phase 3Terminated2021-02-02
NCT02682407OMS721 (narsoplimab)Phase 2Terminated2020-08-25
NCT02222545OMS721 (narsoplimab)Phase 2Completed2020-01-30
NCT02132312OMS302Phase 3Completed2016-09-12
NCT02074410OMS643762Phase 2Terminated2014-10-15
NCT02093689Part 1 OMS302Phase 3Terminated2014-08-01
NCT01952132OMS643762Phase 2Completed2014-04-01
NCT01579565OMS302Phase 3Completed2012-11-01
NCT01406561OMS103HP-SPhase 3Completed2012-11-01
NCT01454063OMS302Phase 3Completed2012-03-01
NCT01193127OMS302 SolutionPhase 2Completed2011-01-01
NCT00857090OMS201Phase 2Completed2010-12-01
NCT00226759OMS103HPPhase 3Completed2010-09-01
NCT00226772OMS103HPPhase 3Completed2010-09-01

Recent catalysts

FDA approvalDec 24, 2025· 164d ago
$OMEROMEROS CORP
yartemlea
“On December 24, 2025, Omeros Corporation (the "Company" or "we") issued a press release announcing that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), an often-fatal complication of stem-cell transplantation driven by activation of the lectin pathway of complement.”
FDA approvalDec 23, 2025· 165d ago· success
$OMEROMEROS CORP
yartemlea
“openFDA ORIG (TYPE 1) approval of YARTEMLEA — application BLA761152”
PDUFASep 25, 2025· 254d ago· unknown
$OMEROMEROS CORP
narsoplimab · hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)
“pursuant to the Prescription Drug User Fee Act ("PDUFA"), was assigned an initial target action date for the FDA decision of September 25, 2025”
CRLOct 18, 2021· 1692d ago
$OMEROMEROS CORP
narsoplimab · hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)
“On October 18, 2021, the Company issued a press release announcing the receipt of a complete response letter from the U.S. Food and Drug Administration (the "FDA") regarding the Company's Biologics License Application ("BLA") for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy ("HSCT-TMA").”
PDUFAOct 17, 2021· 1693d ago· failure
$OMEROMEROS CORP
narsoplimab · hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)
“the Company does not currently expect any such resolution to occur by the October 17, 2021 target action date under the Prescription Drug User Fee Act.”